Education
About Us
Working with TipRanks
Follow Us
DarioHealth Corp (DRIO)
NASDAQ:DRIO
DRIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.54 - $1.93
Previous CloseN/A
Volume780.96K
Average Volume (3M)237.20K
Market Cap
$23.96M
Enterprise Value$31.73M
Total Cash (Recent Filing)$1.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.65
Next Earnings
May 20, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding41,567,017
10 Day Avg. Volume220,700
30 Day Avg. Volume237,196
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.06
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$1.50Price Target Upside167.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
DarioHealth News
PremiumCompany Announcements
DarioHealth Appoints New Auditing Firm PwC MemberPremiumCompany Announcements
DarioHealth’s Earnings Call Highlights Robust Growth
PremiumCompany Announcements
DarioHealth Reports Strong Revenue Growth in 2024---
Bulls Say, Bears Say
Bulls Say
Business ExpansionDRIO announced 10 new client wins in B2B2C and expects to sign an additional 5 new clients by year-end, representing a 35% year-over-year growth in the B2B2C client base.
Earnings4Q revenue of $7.6M beat estimates of $7.3M, driven by stronger-than-expected B2B revenue.
PartnershipsDRIO announced two new strategic partner wins, including a top six global pharma and a medical device company.
Bears Say
Demand EnvironmentThe demand environment for digital health has remained challenged, contributing to several consecutive quarters of revenues coming in below estimates.
Investment ChallengesA challenging demand environment and limited investment pressures revenue growth trajectory and likely prolongs the path to achieving EBITDA breakeven.
Revenue VisibilityThere is limited visibility on DRIO's strategic partnerships channel, which is on track to generate zero revenues in 2024.
---
Ownership Overview
6.21% Insiders
1.49% Mutual Funds
15.44% Other Institutional Investors
75.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $0.54 and its highest was $1.93 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $23.96M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is May 20, 2025 which is in 44 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on Mar 10, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.253.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Undervalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -0.1.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 41,567,017 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went down -8.219%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
---
DarioHealth Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (167.86% Upside)
$1.50 (167.86% Upside)
Blogger Sentiment
Bullish
DRIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 313.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.42%
12-Months-Change
Fundamentals
Return on Equity
-46.09%
Trailing 12-Months
Asset Growth
23.34%
Trailing 12-Months
Company Description
DarioHealth Corp
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
---
DRIO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful product integration, and a solid financial position, indicating positive momentum for DarioHealth. However, the dependency on future client acquisition for profitability and the absence of full-suite integrated sales were notable challenges. Overall, the positive aspects outweighed the lowlights.Read More>---
DRIO Stock 12 Month Forecast
Average Price Target
$1.50
▲(167.86% Upside)
Technical Analysis
Tenax Therapeutics
―
Pulmatrix
―
VYNE Therapeutics
―
Cognition Therapeutics
―
CytoMed Therapeutics Limited
―
Best Analysts Covering DRIO
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-48.38%
reiterated a buy rating 26 days ago
Copying David Grossman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.38% per trade.
---